Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

被引：0
|
作者：
Slamon, D.
Eiermann, W.
Robert, N.
Pienkowski, T.
Martin, M.
Rolski, J.
Chan, A.
Mackey, J.
Liu, M.
Pinter, T.
Valero, V.
Falkson, C.
Fornander, T.
Shiftan, T.
Olsen, S.
Buyse, M.
Kiskartalyi, T.
Landreau, V
Wilson, V
Press, M.
Crown, J.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] GBC, Munich, Germany
[3] US Oncol, Houston, TX USA
[4] Maria Sklosowska Curie Ctr, Warsaw, Poland
[5] GEICAM, Madrid, Spain
[6] MSC Inst, Krakow, Poland
[7] Mt Hosp, Perth, WA, Australia
[8] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[9] Sun Yat Sen Canc Ctr, Taipei, Taiwan
[10] Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary
[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[12] Univ Alabama, Birmingham, AL USA
[13] Onkol Kliniken, Stockholm, Sweden
[14] Sharp Healthcare, San Diego, CA USA
[15] Sanofi Aventis, Paris, France
[16] IDDI, Louvain, Belgium
[17] TRIO CIRG, Paris, France
[18] USC, Los Angeles, CA USA
[19] ICORG, Dublin, Ireland
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：500S / 500S
页数：1
相关论文
共 50 条
  • [1] Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC®T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients:: BCIRG 006 study
    Slamon, D
    Eiermann, W
    Robert, N
    Pienkowski, T
    Martin, M
    Pawlicki, M
    Chan, A
    Smylie, M
    Liu, M
    Falkson, C
    Pinter, T
    Fornander, T
    Shiftan, T
    Valero, V
    Von Minckwitz, G
    Mackey, J
    Tabah-Fisch, J
    Buyse, M
    Lindsay, MA
    Riva, A
    Bee, V
    Pegram, M
    Press, M
    Crown, J
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S5 - S5
  • [2] Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+early breast cancer
    Slamon, D. J.
    Eiermann, W.
    Robert, N. J.
    Giermek, J.
    Martin, M.
    Jasiowka, M.
    Mackey, J. R.
    Chan, A.
    Liu, M-C
    Pinter, T.
    Valero, V.
    Falkson, C.
    Fornander, T.
    Shiftan, T. A.
    Bensfia, S.
    Hitler, S.
    Xu, N.
    Bee-Munteanu, V.
    Drevot, P.
    Press, M. F.
    Crown, J.
    [J]. CANCER RESEARCH, 2016, 76
  • [3] Efficacy results of node-negative HER2-amplified breast cancer subset from BCIRG 006 study: A phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin, and trastuzumab (TCH).
    Valero, V.
    Slamon, D. J.
    Eiermann, W.
    Robert, N. J.
    Pienkowski, T.
    Martin, M.
    Mackey, J. R.
    Lindsay, M. A.
    Bee-Munteanu, V.
    Press, M. F.
    Sauter, G.
    Crown, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Docetaxel, carboplatin and trastuzumab (TCH) and doxorubicin/cyclophosphamide followed by docetaxel/trastuzumab (AC-TH) produce superior disease-free survival (DFS) compared to AC-T in patients (pts) with HER-2 positive early breast cancer (EBC), with increased cardiac toxicity confined to AC-TH: BCIRG 006 study
    不详
    [J]. EJC SUPPLEMENTS, 2006, 4 (02): : 108 - 109
  • [5] Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC®T) in Her-2/neu negative early breast cancer patients with positive axillary lymph nodes:: Interim analysis of the BCIRG 005 study
    Eiermann, W
    Pienkowski, T
    Crown, J
    Chap, L
    Pawlicki, M
    Martin, M
    Chan, A
    Saleh, M
    Sehdev, S
    Provencher, L
    Von Minckwitz, G
    Semiglazov, V
    Slamon, D
    Tabah-Fisch, I
    Buyse, M
    Riva, A
    Taupin, H
    Sauter, G
    Mackey, J
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S62 - S63
  • [6] BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC → T) in women with Her-2/neu negative axillary lymph node positive early breast cancer.
    Eiermann, W.
    Pienkowski, T.
    Crown, J.
    Chap, L.
    Pawlicki, M.
    Martin, M.
    Saleh, M.
    Sehdev, S.
    Provencher, L.
    Von Minckwitz, G.
    Semiglazov, V
    Slamon, D.
    Tabah-Fish, I
    Buyse, M.
    Riva, A.
    Taupin, H.
    Sauter, G.
    Mackey, J.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 82S - 82S
  • [7] A randomized, opened, phase II trial assessing the efficacy and safety of ATH-TH(doxorubicin/docetaxel/trastuzumab followed by docetaxel/trastuzumab) versus TCH(docetaxel/carboplatin/trastuzumab) as neoadjuvant treatment in HER2-positive breast cancer
    Wang, Tao
    Zhou, Jin-Mei
    Hao, Xiao-Peng
    Zhang, Hui-Qaing
    Zhang, Shao-Hua
    Bian, Li
    Jiang, Ze-Fei
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [8] A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer
    Schneeweiss, A.
    Marme, F.
    Ruiz, A.
    Manikhas, A. G.
    Bottini, A.
    Wolf, M.
    Sinn, H. -P.
    Mansouri, K.
    Kennedy, L.
    Bauknecht, T.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (03) : 609 - 617
  • [9] Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer:: A randomized phase II trial
    Schneeweiss, Andreas
    Lauschner, Ilka
    Ruiz, Amparo
    Guerrero, Angel
    Sanchez-Rovira, Pedro
    Segui, Miguel Angel
    Goerke, Kay
    Wolf, Michael
    Manikhas, Alexey G.
    Wacker, Juergen
    Marme, Frederik
    Lichter, Peter
    Sinn, Hans-Peter
    Sohn, Christof
    Mansouri, Kambiz
    Bauknecht, Thomas
    Hahn, Meinhard
    [J]. CLINICAL BREAST CANCER, 2007, 7 (07) : 555 - 558
  • [10] BCIRG 006: Superior cardiac safety of adjuvant docetaxel (T), carboplatin (C) and trastuzumab (H) compared to doxorubicin (A) and cyclophosphamide (Cyc) followed by TH in patients with early stage breast cancer and altered HER2 gene.
    Slamon, D.
    Eiermann, W.
    Robert, N.
    Pienkowski, T.
    Martin, M.
    Pawlicki, M.
    Chan, M.
    Buyse, M.
    Bee, V.
    Crown, J.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 74 - 74
12345